A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Firdapse Momentum And Growing Agamree Contribution

Simply Wall St.05:08

AdvertisementStock move and what sparked it Catalyst Pharmaceuticals (CPRX) drew attention after a 6.7% share price move in the last session on higher trading volume, as investors focused on Firdapse ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630331911?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-27 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630331911","market":"us","top_or_hot":-1,"title":"A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Firdapse Momentum And Growing Agamree Contribution","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementStock move and what sparked it Catalyst Pharmaceuticals (CPRX) drew attention after a 6.7% share price move in the last session on higher trading volume, as investors focused on Firdapse ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/a-look-at-catalyst-pharmaceuticals-cprx-valuation-after-fird\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Firdapse Momentum And Growing Agamree Contribution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Catalyst Pharmaceuticals (CPRX) Valuation After Firdapse Momentum And Growing Agamree Contribution\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-27 05:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/a-look-at-catalyst-pharmaceuticals-cprx-valuation-after-fird><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementStock move and what sparked it Catalyst Pharmaceuticals (CPRX) drew attention after a 6.7% share price move in the last session on higher trading volume, as investors focused on Firdapse ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/a-look-at-catalyst-pharmaceuticals-cprx-valuation-after-fird\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0034390439.USD","symbol_name":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/a-look-at-catalyst-pharmaceuticals-cprx-valuation-after-fird","article_id":"2630331911","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/a-look-at-catalyst-pharmaceuticals-cprx-valuation-after-fird","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630331911","pubTimestamp":1777237691,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Stock move and what sparked it\nCatalyst Pharmaceuticals (CPRX) drew attention after a 6.7% share price move in the last session on higher trading volume, as investors focused on Firdapse momentum, Agamree uptake, and upcoming earnings expectations.\nSee our latest analysis for Catalyst Pharmaceuticals.\nThat 6.7% move came on top of a 16.97% 30 day share price return and an 18.23% year to date share price return, while total shareholder return over five years has been very large, suggesting...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","CPRX":"Catalyst Pharmaceutical Partners","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4139":"生物科技"},"translate_title":"Firdapse势头和Agamree贡献不断增长后Catalyst Pharmaceuticals(CPRX)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"CPRX":1.5},"content_text":"AdvertisementStock move and what sparked it Catalyst Pharmaceuticals (CPRX) drew attention after a 6.7% share price move in the last session on higher trading volume, as investors focused on Firdapse momentum, Agamree uptake, and upcoming earnings expectations. See our latest analysis for Catalyst Pharmaceuticals. That 6.7% move came on top of a 16.97% 30 day share price return and an 18.23% year to date share price return, while total shareholder return over five years has been very large, suggesting momentum has been building as investors reassess growth prospects and risks around its rare disease portfolio. If strong moves in rare disease names have caught your attention, this can be a good moment to see what else fits that profile across 33 healthcare AI stocks With shares up strongly over the past year, and the stock trading below the average analyst price target and an internal intrinsic value estimate, you now have to ask: Is there still a buying opportunity here, or is the market already pricing in future growth? Preferred Price-to-Earnings of 15.6x: Is it justified? On a P/E of 15.6x, Catalyst Pharmaceuticals trades below both the US Biotechs industry average of 17.8x and a peer average of 31.1x, while sitting slightly above an estimated fair P/E of 15x. The P/E ratio compares the current share price to earnings per share, so it indicates how much investors are paying for each dollar of current profit. For a commercial stage rare disease company with positive net income of $214.3m and high quality earnings, this makes the P/E a useful snapshot of how the market is pricing its existing profit base. Here, the picture is mixed. The stock looks inexpensive relative to both the broader Biotechs group and closer peers, which suggests the market is not assigning a premium to its 22.5% Return on Equity or its 5 year earnings growth track record. At the same time, the small premium to the estimated fair P/E suggests a level the multiple might gravitate toward if expectations on future earnings growth, currently forecast at 8.7% per year, stay intact. Compared with the US Biotechs industry P/E of 17.8x and the peer average of 31.1x, the current 15.6x multiple is materially lower. This indicates a clear valuation gap that could narrow if sentiment moves closer to that fair P/E reference point. Explore the SWS fair ratio for Catalyst Pharmaceuticals Result: Price-to-earnings of 15.6x (UNDERVALUED) However, you also need to watch for concentration risk in a rare disease portfolio and for any shift in sentiment if revenue or earnings momentum slows. Find out about the key risks to this Catalyst Pharmaceuticals narrative. Another view: DCF suggests a much larger gap If the 15.6x P/E hints at a mild discount, the SWS DCF model takes a far stronger stance, putting fair value at $62.27 per share versus a market price of $27.37, or a 56% discount. When two methods diverge this much, which signal is more reliable? Look into how the SWS DCF model arrives at its fair value. CPRX Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Catalyst Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 54 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of optimism and caution has you curious, review the numbers yourself and evaluate the potential upside drivers identified in the 4 key rewards Looking for more investment ideas? If Catalyst Pharmaceuticals has sharpened your interest, do not stop here. Broaden your watchlist with focused ideas that match your style and keep your capital working intelligently.  Target potential value opportunities by scanning 54 high quality undervalued stocks that pair quality fundamentals with prices the market may be underappreciating. Strengthen your income stream by reviewing 13 dividend fortresses built around companies offering higher yields with an emphasis on resilience. Prioritise resilience by checking 73 resilient stocks with low risk scores that highlight businesses with steadier risk profiles for calmer portfolio swings.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630331911","isCrawlerRequest":true}